TrialThe New England journal of medicine2003

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

James C Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.